Placebo + ATYR1940
Phase 1/2Completed 0 views this week 0 watching💤 Quiet
Interest: 22/100
22
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Facioscapulohumeral Muscular Dystrophy (FSHD)
Conditions
Facioscapulohumeral Muscular Dystrophy (FSHD)
Trial Timeline
Sep 4, 2014 → Dec 14, 2015
NCT ID
NCT02239224About Placebo + ATYR1940
Placebo + ATYR1940 is a phase 1/2 stage product being developed by aTyr Pharma for Facioscapulohumeral Muscular Dystrophy (FSHD). The current trial status is completed. This product is registered under clinical trial identifier NCT02239224. Target conditions include Facioscapulohumeral Muscular Dystrophy (FSHD).
What happened to similar drugs?
0 of 2 similar drugs in Facioscapulohumeral Muscular Dystrophy (FSHD) were approved
Approved (0) Terminated (1) Active (1)
Hype Score Breakdown
Clinical
9
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02239224 | Phase 1/2 | Completed |
Competing Products
12 competing products in Facioscapulohumeral Muscular Dystrophy (FSHD)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ACE-083 + ACE-083 or placebo | Merck | Phase 2 | 27 |
| ACE-083 | Merck | Phase 2 | 27 |
| Placebo + RO7204239 | Roche | Phase 2 | 39 |
| AOC-1020 + Placebo | Avidity Biosciences | Phase 3 | 44 |
| Apitegromab + Placebo | Scholar Rock Holding | Phase 2 | 39 |
| Losmapimod oral tablet + Placebo oral tablet | Fulcrum Therapeutics | Phase 2 | 25 |
| Losmapimod + Placebo oral tablet | Fulcrum Therapeutics | Phase 3 | 22 |
| Losmapimod | Fulcrum Therapeutics | Phase 2 | 17 |
| Losmapimod | Fulcrum Therapeutics | Phase 2 | 17 |
| ATYR1940 | aTyr Pharma | Phase 1/2 | 22 |
| ATYR1940 | aTyr Pharma | Phase 1/2 | 22 |
| ATYR1940 | aTyr Pharma | Phase 1/2 | 22 |